NJ’s Life Sciences Boom

While more life sciences companies are choosing to locate and expand in New Jersey, a more competitive business climate could be the key to unlocking the industry's full potential.

By Jim Pytell, Managing Editor On Mar 5, 2026

New Jersey has been known as “The Medicine Chest of the World” for well over a century. The nickname dates back to the late 19th and early 20th centuries, when major pharmaceutical and medical companies began establishing roots in the state – with one of the earliest and most influential examples being Johnson & Johnson, which opened its factory in New Brunswick in 1886, helping to spark a unique combination of industry concentration, innovation, and global influence in medicine.

Today, the industry is experiencing palpable momentum, as life sciences and biopharmaceutical companies choose to locate in and expand existing facilities in the state at an exciting rate.

“This latest influx reflects the growing attractiveness of our innovation ecosystem, which former Gov. Phil Murphy has worked to improve over the past eight years,” says Chrissy Buteas, president and CEO of the HealthCare Institute of New Jersey (HINJ).

She cites an unparalleled concentration of life sciences talent, world-class research institutions, strong education systems, and a deep bench of experienced companies – large and small – as factors behind the industry’s continued growth in the state.

“Add to that the proximity to major markets, robust infrastructure, one of the most highly skilled workforces in the world, and a growing network of innovation hubs and specialized manufacturing capabilities, and New Jersey presents a compelling environment for companies looking to grow,” Buteas adds.

Debbie Hart, president and CEO of BioNJ, points to long-established companies such as Insmed (Bridgewater), Genmab (Plainsboro) and Ascendis Pharma (Princeton) having come into their own over the past few years, expanding their respective footprints in New Jersey, while state government investments in innovative programs and incentives have also fueled newly formed companies such as NanoNewron (Union) and VITRUVIAE (Nutley).

“Combined with the successful business-attraction efforts of Choose New Jersey bringing companies such as Enzene (Pennington) and Biocon Biologics (Bridgewater) here, the state has seen an unprecedented uptick in ribbon cuttings and groundbreakings,” Hart says.

Economic Impact

According to BioNJ, New Jersey is the nation’s second-largest biopharma hub, powered by a GDP of $121 billion representing 7.8% of the state’s economy, more than double the US average.

“Consider Enzene Biosciences, which opened its first US biopharmaceutical manufacturing facility late last year in Hopewell and expects to create 200-300 highly skilled jobs as it scales,” Hart says. “Likewise, Genmab has undertaken two major expansions at the Princeton Forrestal Innovation Center over the past five years and has committed to adding more than 300 jobs in Middlesex County. Together, these investments underscore the powerful, long-term impact the industry’s continued growth is having across the state.”

“[The locations and expansions we are seeing] deliver broad and durable economic benefits to local communities,” Buteas says. “These firms create high-paying jobs across a wide range of skill levels while also supporting secondary employment in construction, professional services, logistics, and advanced manufacturing.”

She adds that new facilities also often catalyze redevelopment, infrastructure investment, and increased demand for housing and commercial real estate. “Importantly, life sciences growth tends to be resilient and long-term, anchoring regional economies and contributing to stable tax bases and community vitality,” Buteas says.